Boaz Wong1,2, Michael M Vickers2,3, Paul Wheatley-Price2,3. 1. Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. 2. Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. 3. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
Abstract
BACKGROUND: Cancer of unknown primary (CUP) describes patients with metastatic disease without an identified primary tumor site. Successful diagnosis and treatment of these patients remains difficult. Published guidelines on CUP have highlighted "favorable" subtype groups. We investigated a series of CUP patients to review adherence to guidelines, and identification of primary cancers or "favorable" subtypes. METHODS: Patients with histologically confirmed CUP at an academic institution from 2012 to 2018 were identified. Patient demographics, tumor presentation, diagnostic work-up and treatment information were retrospectively collected from electronic data records for descriptive analysis and compared to published clinical guidelines. The primary endpoint was the proportion of patients where the primary site was identified. Multivariable logistic regression models were used to identify factors associated with primary site identification. Kaplan-Meier survival curves were used to determine factors associated with poorer OS. RESULTS: Three hundred and five patients were included with a median follow-up time of 4.3 months. Primary tumor sites were identified in 109 patients (37.5%), which was most commonly lung cancer (33%). Statistical analyses did not identify any demographic or initial presentation factors associated with identifying the primary or not. More diagnostic tests did not increase the likelihood of primary site identification (P=0.44). Patients with an identified primary did not have longer OS than other patients (median 5.2 months vs. 4.7 months, P=0.47). 57 patients (18.7%) who had a defined "favorable" subtype experienced superior OS (36.6 months vs. 3.8 months; P<0.0001). Further, patients with good prognostic status who followed published treatment guidelines had longer OS (17.6 months vs. 13.2 months; P=0.04). CONCLUSIONS: CUP remains a difficult cancer to diagnose and treat. These results suggest identifying the primary has less impact than anticipated, but particular efforts to identify patients with "favorable" subtypes of CUP is important prognostically.
BACKGROUND: Cancer of unknown primary (CUP) describes patients with metastatic disease without an identified primary tumor site. Successful diagnosis and treatment of these patients remains difficult. Published guidelines on CUP have highlighted "favorable" subtype groups. We investigated a series of CUP patients to review adherence to guidelines, and identification of primary cancers or "favorable" subtypes. METHODS: Patients with histologically confirmed CUP at an academic institution from 2012 to 2018 were identified. Patient demographics, tumor presentation, diagnostic work-up and treatment information were retrospectively collected from electronic data records for descriptive analysis and compared to published clinical guidelines. The primary endpoint was the proportion of patients where the primary site was identified. Multivariable logistic regression models were used to identify factors associated with primary site identification. Kaplan-Meier survival curves were used to determine factors associated with poorer OS. RESULTS: Three hundred and five patients were included with a median follow-up time of 4.3 months. Primary tumor sites were identified in 109 patients (37.5%), which was most commonly lung cancer (33%). Statistical analyses did not identify any demographic or initial presentation factors associated with identifying the primary or not. More diagnostic tests did not increase the likelihood of primary site identification (P=0.44). Patients with an identified primary did not have longer OS than other patients (median 5.2 months vs. 4.7 months, P=0.47). 57 patients (18.7%) who had a defined "favorable" subtype experienced superior OS (36.6 months vs. 3.8 months; P<0.0001). Further, patients with good prognostic status who followed published treatment guidelines had longer OS (17.6 months vs. 13.2 months; P=0.04). CONCLUSIONS: CUP remains a difficult cancer to diagnose and treat. These results suggest identifying the primary has less impact than anticipated, but particular efforts to identify patients with "favorable" subtypes of CUP is important prognostically.
Authors: John D Hainsworth; Catherine A Schnabel; Mark G Erlander; David W Haines; F Anthony Greco Journal: Clin Colorectal Cancer Date: 2011-10-14 Impact factor: 4.481
Authors: Chong S Kim; Malek B Hannouf; Sisira Sarma; George B Rodrigues; Peter K Rogan; Salaheddin M Mahmud; Eric Winquist; Muriel Brackstone; Gregory S Zaric Journal: Acta Oncol Date: 2015-03-31 Impact factor: 4.089
Authors: F A Greco; K Oien; M Erlander; R Osborne; G Varadhachary; J Bridgewater; D Cohen; H Wasan Journal: Ann Oncol Date: 2011-06-27 Impact factor: 32.976
Authors: D Verver; Aam van der Veldt; Acj van Akkooi; C Verhoef; D J Grünhagen; W J Louwman Journal: Int J Cancer Date: 2019-03-20 Impact factor: 7.396
Authors: R Bugat; A Bataillard; T Lesimple; J J Voigt; S Culine; A Lortholary; Y Merrouche; G Ganem; M C Kaminsky; S Negrier; M Perol; C Laforêt; P Bedossa; G Bertrand; J M Coindre; K Fizazi Journal: Br J Cancer Date: 2003-08 Impact factor: 7.640